JP MORGAN/CALL/MODERNA/145/0.1/19.07.24 | Delayed Börse Stuttgart 09:03:43 02/07/2024 BST | ||
| 0.033 EUR | -5.71% |
|
| Current month | -26.67% | ||
| 1 month | -96.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 02/07/24 | 0.033 | -5.71% |
| 01/07/24 | 0.035 | -22.22% |
| 28/06/24 | 0.045 | -31.82% |
| 27/06/24 | 0.066 | -28.26% |
| 26/06/24 | 0.092 | -77.00% |
Delayed Quote Börse Stuttgart
Last update July 02, 2024 at 09:03 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | J.P. Morgan |
| WKN | JS8PKH |
| ISIN | DE000JS8PKH3 |
| Date issued | 27/02/2023 |
| Strike | 145 $ |
| Maturity | 19/07/2024 (17 Days) |
| Parity | 10 : 1 |
| Emission price | 3.92 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.79 € |
|---|---|
| Lowest since issue | 0.032 € |
| Spread | 0.097 € |
| Spread % | 74.62% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
117.1
USD
Average target price
145.9
USD
Spread / Average Target
+24.59%
- Stock Market
- Warrants
- Warrant
